Literature DB >> 12480661

Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

P Ranganathan1, S Eisen, W M Yokoyama, H L McLeod.   

Abstract

Methotrexate (MTX) remains the most commonly used disease modifying antirheumatic drug in rheumatoid arthritis (RA) because of its cost and experience in its use, despite the availability of new treatments such as leflunomide and the biological agents. However, a significant number of patients with RA either do not benefit from the drug or are unable to tolerate it. Pharmacogenetic approaches may help optimise treatment with MTX, and also other agents, in RA.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12480661      PMCID： PMC1754300          DOI： 10.1136/ard.62.1.4

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  72 in total

Review 1.  Polyglutamation of methotrexate. Is methotrexate a prodrug?

Authors:  B A Chabner; C J Allegra; G A Curt; N J Clendeninn; J Baram; S Koizumi; J C Drake; J Jolivet
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

2.  Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates.

Authors:  J M Kremer; J Galivan; A Streckfuss; B Kamen
Journal:  Arthritis Rheum       Date:  1986-07

3.  The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis.

Authors:  S L Morgan; J E Baggott; W H Vaughn; P K Young; J V Austin; C L Krumdieck; G S Alarcón
Journal:  Arthritis Rheum       Date:  1990-01

4.  Methotrexate and trimethoprim-sulphamethoxazole--a potentially hazardous combination.

Authors:  H Groenendal; F H Rampen
Journal:  Clin Exp Dermatol       Date:  1990-09       Impact factor: 3.470

5.  Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.

Authors:  P A Andersen; S G West; J R O'Dell; C S Via; R G Claypool; B L Kotzin
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

6.  Central nervous system toxicity associated with weekly low-dose methotrexate treatment.

Authors:  R Wernick; D L Smith
Journal:  Arthritis Rheum       Date:  1989-06

7.  Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment.

Authors:  G S Alarcón; I C Tracy; W D Blackburn
Journal:  Arthritis Rheum       Date:  1989-06

8.  Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial.

Authors:  H J Williams; R F Willkens; C O Samuelson; G S Alarcón; M Guttadauria; C Yarboro; R P Polisson; S R Weiner; M E Luggen; L M Billingsley
Journal:  Arthritis Rheum       Date:  1985-07

9.  Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase.

Authors:  S S Kang; J Zhou; P W Wong; J Kowalisyn; G Strokosch
Journal:  Am J Hum Genet       Date:  1988-10       Impact factor: 11.025

10.  Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate.

Authors:  C W Carson; G W Cannon; M J Egger; J R Ward; D O Clegg
Journal:  Semin Arthritis Rheum       Date:  1987-02       Impact factor: 5.532
View more
  15 in total

Review 1.  T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias.

Authors:  Rebecca J Watters; Xin Liu; Thomas P Loughran
Journal:  Leuk Lymphoma       Date:  2011-07-13

2.  Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.

Authors:  Niti Mittal; Aman Sharma; Vinu Jose; Rakesh Mittal; Ajay Wanchu; Pradeep Bambery
Journal:  Rheumatol Int       Date:  2010-12-16       Impact factor: 2.631

3.  Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation.

Authors:  David L Delano; M Carmen Montesinos; Avani Desai; Tuere Wilder; Patricia Fernandez; Peter D'Eustachio; Tim Wiltshire; Bruce N Cronstein
Journal:  Arthritis Rheum       Date:  2005-08

4.  Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.

Authors:  T Dervieux; D Furst; D O Lein; R Capps; K Smith; J Caldwell; J Kremer
Journal:  Ann Rheum Dis       Date:  2005-01-27       Impact factor: 19.103

5.  Associations between C677T and A1298C polymorphisms of MTHFR and susceptibility to rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Yi Yuan; Wenjing Shao; Yuying Li
Journal:  Rheumatol Int       Date:  2017-02-07       Impact factor: 2.631

6.  Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype.

Authors:  Halima Moncrieffe; Anne Hinks; Simona Ursu; Laura Kassoumeri; Angela Etheridge; Mike Hubank; Paul Martin; Tracey Weiler; David N Glass; Susan D Thompson; Wendy Thomson; Lucy R Wedderburn
Journal:  Pharmacogenet Genomics       Date:  2010-11       Impact factor: 2.089

7.  Population distribution of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C risk alleles for methotrexate toxicity in Israel.

Authors:  Edna Efrati; Hela Elkin; Sagi Nahum; Norberto Krivoy
Journal:  Rheumatol Int       Date:  2012-07-31       Impact factor: 2.631

8.  Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity.

Authors:  Mark C Fisher; Bruce N Cronstein
Journal:  J Rheumatol       Date:  2009-02-04       Impact factor: 4.666

Review 9.  Ameliorating Role Exerted by Al-Hijamah in Autoimmune Diseases: Effect on Serum Autoantibodies and Inflammatory Mediators.

Authors:  Hussam Baghdadi; Nada Abdel-Aziz; Nagwa Sayed Ahmed; Hany Salah Mahmoud; Ayman Barghash; Abdullah Nasrat; Manal Mohamed Helmy Nabo; Salah Mohamed El Sayed
Journal:  Int J Health Sci (Qassim)       Date:  2015-04

10.  Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model.

Authors:  Misato Hashizume; Hiroto Yoshida; Keisuke Tanaka; Miho Suzuki; Isao Matsumoto; Takayuki Sumida; Masahiko Mihara
Journal:  Arthritis Res Ther       Date:  2012-04-30       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.